<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231750</url>
  </required_header>
  <id_info>
    <org_study_id>UC 060559</org_study_id>
    <nct_id>NCT01231750</nct_id>
  </id_info>
  <brief_title>Efficacy of Topical Capsaicin Cream for Stable Angina</brief_title>
  <acronym>TOPCAP</acronym>
  <official_title>A Randomized, Placebo-Controlled, Cross-Over Study to Assess the Safety and Efficacy of TOPical CAPsaicin With Stable Angina (TOPCAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neal Weintraub</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that application of topical capsaicin in
      patients with stable angina will result in improved exercise tolerance and reduced cardiac
      ischemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with stable angina on medical therapy who are capable of exercising on a treadmill
      and have an interpretable ECG for ischemia will be enrolled in the study, which entails
      performing two treadmill tests approximately one week apart following topical treatment with
      placebo cream or topical capsaicin (randomized in crossover fashion). Patients will be
      monitored for exercise tolerance, anginal symptoms, ECG for ischemia/arrhythmia, and
      hemodynamic responses.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to identify study population to achieve number expected
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom-limited Exercise Duration as an Indicator of Exercise Capacity</measure>
    <time_frame>Application was 45 minutes prior to exercise</time_frame>
    <description>Subjects walked on the treadmill as long as they could tolerate, symptom-limited.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-to-onset of 1mm ST Segment Depression</measure>
    <time_frame>Application was 45 minutes prior to exercise</time_frame>
    <description>Continuous ECG was recorded during exercise. ECG was reviewed by a board-certified cardiologist.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-to-onset of Angina or Angina Equivalent Symptoms</measure>
    <time_frame>Application was 45 minutes prior to exercise</time_frame>
    <description>Onset of angina or angina-equivalent symptoms was assessed from beginning of exercise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal ST Depression</measure>
    <time_frame>Application was 45 minutes prior to exercise</time_frame>
    <description>Exercise ECG data was reviewed by a board certified cardiologist to assess maximal ST depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal Estimated Workload (in METS)</measure>
    <time_frame>Application was 45 minutes prior to exercise</time_frame>
    <description>Maximal estimated workload (in METS) was measured during exercise tolerance test (ETT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of Reversible Perfusion Defect in SPECT With Wall Motion Assessment (Phase 2)</measure>
    <time_frame>Phase 2 was not done.</time_frame>
    <description>Phase 2 of the study involving nuclear imaging was not done because the study was stopped early for lack of enrollment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Angina Was Measured.</measure>
    <time_frame>Application was 45 minutes prior to exercise</time_frame>
    <description>Severity of angina was measured using numerical score 1 to 10, where 10 is the worst intensity and 1 is the least.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>0.1% Capsaicin Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1% capsaicin cream spread 8cm x 15cm on abdomen, once, 45 minutes prior to exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive cream, 4cm spread 8cm x 15cm on the abdomen, once, 45 minutes prior to exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capsaicin</intervention_name>
    <description>0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise</description>
    <arm_group_label>0.1% Capsaicin Cream</arm_group_label>
    <other_name>capsaicin cream 0.1%, generic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo cream</intervention_name>
    <description>cream, 4cm spread over 8cm x 15cm area of skin</description>
    <arm_group_label>Placebo Cream</arm_group_label>
    <other_name>cream, placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; or = 3 month history of chronic, stable, angina triggered by physical effort or
             mental/emotional stress

          -  documented stress-induced ST depression, reversible perfusion imaging, or wall motion
             abnormality or CAD &gt;50%

          -  Canadian Cardiovascular (CV) Class I-III

          -  Receiving medical therapy for &gt; or = 2 months

          -  Ability to perform Bruce Protocol treadmill test

          -  non-pregnant female

        Exclusion Criteria:

          -  unstable angina

          -  revasc within 2 months

          -  Myocardial infarction (MI) within 2 months

          -  congestive heart failure (CHF) hospitalization within 2 months

          -  New York Heart Association (NYHA) class III or IV

          -  left ventricular ejection fraction (LVEF) &lt; 25%

          -  abnormal ECG; Acute changes on ECG

          -  Currently receiving treatment with investigational drugs/devices

          -  Uncontrolled hypertension

          -  contraindication to exercise stress testing

          -  allergy to red peppers or capsaicin

          -  skin deformity, scar, or rash at application site

          -  abdominal surgery within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faisal M Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati Physicians, Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2010</study_first_submitted>
  <study_first_submitted_qc>October 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2010</study_first_posted>
  <results_first_submitted>June 25, 2013</results_first_submitted>
  <results_first_submitted_qc>June 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 25, 2015</results_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Neal Weintraub</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment goal not met.</recruitment_details>
      <pre_assignment_details>Inclusion and exclusion criteria proved a large screening volume to yield few participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.1% Capsaicin Cream First, Then Placebo</title>
          <description>Capsaicin : 0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then 0.1% Capsaicin</title>
          <description>Inactive substance, 4cm spread 8cm x 15cm on skin, once, 45 minutes prior to exercise
Placebo cream : cream, 4cm spread over 8cm x 15cm area of skin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.1% Capsaicin Cream First, Then Placebo</title>
          <description>Capsaicin : 0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then 0.1% Capsaicin</title>
          <description>Inactive substance, 4cm spread 8cm x 15cm on skin, once, 45 minutes prior to exercise
Placebo cream : cream, 4cm spread over 8cm x 15cm area of skin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Symptom-limited Exercise Duration as an Indicator of Exercise Capacity</title>
        <description>Subjects walked on the treadmill as long as they could tolerate, symptom-limited.</description>
        <time_frame>Application was 45 minutes prior to exercise</time_frame>
        <population>Data collected are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Capsaicin Cream First, Then Placebo</title>
            <description>Capsaicin : 0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then 0.1% Capsaicin</title>
            <description>Inactive substance, 4cm spread 8cm x 15cm on skin, once, 45 minutes prior to exercise
Placebo cream : cream, 4cm spread over 8cm x 15cm area of skin</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom-limited Exercise Duration as an Indicator of Exercise Capacity</title>
          <description>Subjects walked on the treadmill as long as they could tolerate, symptom-limited.</description>
          <population>Data collected are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time-to-onset of 1mm ST Segment Depression</title>
        <description>Continuous ECG was recorded during exercise. ECG was reviewed by a board-certified cardiologist.</description>
        <time_frame>Application was 45 minutes prior to exercise</time_frame>
        <population>Data collected are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Capsaicin Cream First, Then Placebo</title>
            <description>Capsaicin : 0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then 0.1% Capsaicin</title>
            <description>Inactive substance, 4cm spread 8cm x 15cm on skin, once, 45 minutes prior to exercise
Placebo cream : cream, 4cm spread over 8cm x 15cm area of skin</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-onset of 1mm ST Segment Depression</title>
          <description>Continuous ECG was recorded during exercise. ECG was reviewed by a board-certified cardiologist.</description>
          <population>Data collected are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time-to-onset of Angina or Angina Equivalent Symptoms</title>
        <description>Onset of angina or angina-equivalent symptoms was assessed from beginning of exercise.</description>
        <time_frame>Application was 45 minutes prior to exercise</time_frame>
        <population>Data collected are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Capsaicin Cream First, Then Placebo</title>
            <description>Capsaicin : 0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then 0.1% Capsaicin</title>
            <description>Inactive substance, 4cm spread 8cm x 15cm on skin, once, 45 minutes prior to exercise
Placebo cream : cream, 4cm spread over 8cm x 15cm area of skin</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-onset of Angina or Angina Equivalent Symptoms</title>
          <description>Onset of angina or angina-equivalent symptoms was assessed from beginning of exercise.</description>
          <population>Data collected are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximal ST Depression</title>
        <description>Exercise ECG data was reviewed by a board certified cardiologist to assess maximal ST depression.</description>
        <time_frame>Application was 45 minutes prior to exercise</time_frame>
        <population>Data collected are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Capsaicin Cream First, Then Placebo</title>
            <description>Capsaicin : 0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then 0.1% Capsaicin</title>
            <description>Inactive substance, 4cm spread 8cm x 15cm on skin, once, 45 minutes prior to exercise
Placebo cream : cream, 4cm spread over 8cm x 15cm area of skin</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal ST Depression</title>
          <description>Exercise ECG data was reviewed by a board certified cardiologist to assess maximal ST depression.</description>
          <population>Data collected are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximal Estimated Workload (in METS)</title>
        <description>Maximal estimated workload (in METS) was measured during exercise tolerance test (ETT).</description>
        <time_frame>Application was 45 minutes prior to exercise</time_frame>
        <population>Data collected are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Capsaicin Cream First, Then Placebo</title>
            <description>Capsaicin : 0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then 0.1% Capsaicin</title>
            <description>Inactive substance, 4cm spread 8cm x 15cm on skin, once, 45 minutes prior to exercise
Placebo cream : cream, 4cm spread over 8cm x 15cm area of skin</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Estimated Workload (in METS)</title>
          <description>Maximal estimated workload (in METS) was measured during exercise tolerance test (ETT).</description>
          <population>Data collected are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Magnitude of Reversible Perfusion Defect in SPECT With Wall Motion Assessment (Phase 2)</title>
        <description>Phase 2 of the study involving nuclear imaging was not done because the study was stopped early for lack of enrollment.</description>
        <time_frame>Phase 2 was not done.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.1% Capsaicin Cream First, Then Placebo</title>
            <description>Capsaicin : 0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then 0.1% Capsaicin</title>
            <description>Inactive substance, 4cm spread 8cm x 15cm on skin, once, 45 minutes prior to exercise
Placebo cream : cream, 4cm spread over 8cm x 15cm area of skin</description>
          </group>
        </group_list>
        <measure>
          <title>Magnitude of Reversible Perfusion Defect in SPECT With Wall Motion Assessment (Phase 2)</title>
          <description>Phase 2 of the study involving nuclear imaging was not done because the study was stopped early for lack of enrollment.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severity of Angina Was Measured.</title>
        <description>Severity of angina was measured using numerical score 1 to 10, where 10 is the worst intensity and 1 is the least.</description>
        <time_frame>Application was 45 minutes prior to exercise</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <desc>Adverse events were assessed, but none observed.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.1% Capsaicin Cream First, Then Placebo</title>
          <description>Capsaicin : 0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise</description>
        </group>
        <group group_id="E2">
          <title>Placebo First, Then 0.1% Capsaicin</title>
          <description>Inactive substance, 4cm spread 8cm x 15cm on skin, once, 45 minutes prior to exercise
Placebo cream : cream, 4cm spread over 8cm x 15cm area of skin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Faisal Khan</name_or_title>
      <organization>University of Cincinnati</organization>
      <phone>513-558-4272</phone>
      <email>faisal.khan@uc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

